Stockscreener 앱 받기
23.86
1.69%
-0.41
시장 영업 전:
24.28
0.42
+1.76%
Maze Therapeutics Inc 주식(MAZE)의 최신 뉴스
Maze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And Risk - Yahoo Finance
MAZE Q1 2026 Earnings: Narrower Loss Surprises Analysts Amid Pipeline ProgressEarnings Acceleration Picks - The League of Women Voters of Texas
Maze Therapeutics (MAZE) price target increased by 11.37% to 44.12 - MSN
Maze Therapeutics Shareholders Elect Directors, Ratify Auditor - TipRanks
[Form 4] Maze Therapeutics, Inc. Insider Trading Activity - Stock Titan
Maze Therapeutics (MAZE) director receives grant of 18,000 stock options exercisable at $23.58 - Stock Titan
Director Richard Scheller receives 18,000 Maze Therapeutics (MAZE) stock options - Stock Titan
Maze Therapeutics (MAZE) director Herve Hoppenot awarded 18,000 stock options at $23.58 - Stock Titan
18,000 Maze Therapeutics (MAZE) options granted to director Andrews - Stock Titan
Maze Therapeutics (MAZE) shareholders elect directors and ratify Ernst & Young - Stock Titan
MAZE: Lead assets show strong efficacy and safety, with pivotal trials and key data readouts set for 2026–2027 - TradingView
MAZE: Directors and auditor ratified by majority vote; no shareholder questions submitted - TradingView
MAZE: Both director nominees and the auditor appointment were approved by majority vote - TradingView
MAZE Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift StockBasic EPS Analysis - newsline.com
Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right Now - Insider Monkey
Maze Therapeutics CEO Sells Shares Worth Around 847000 Dollars - HarianBasis.co
8 Oversold Stocks to Buy Right Now - insidermonkey.com
Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors? - Yahoo Finance
Maze Therapeutics president sells $381k in common stock By Investing.com - Investing.com Australia
Maze Therapeutics president sells $381k in common stock - Investing.com
Maze Therapeutics (MAZE) CEO’s family trusts sell 6,643 shares - Stock Titan
Maze Therapeutics (MAZE) CMO sells 14,853 shares after option exercise - Stock Titan
Maze Therapeutics to Participate in Two Upcoming Investor Conferences - 富途牛牛
Maze Therapeutics (MAZE) CSBO exercises options, sells 7,500 shares under 10b5-1 plan - Stock Titan
Why Is Maze Therapeutics, Inc. (MAZE) Stock Down Today? - Meyka
Coloma trusts sell MAZE shares (MAZE) under Rule 144 notice - Stock Titan
Maze Therapeutics (MAZE) Edges Higher, Consolidating Between Support and ResistanceEarnings Miss Risk - The Legal Advocate
Maze Therapeutics Inc. (MAZE) Edges Higher, Tests Key Resistance ZoneFibonacci Retracement - newsline.com
Maze Therapeutics (MAZE) Edges Higher: Biotech Stock Tests Key Technical LevelsHagopian Line - The Legal Advocate
Maze Therapeutics (MAZE) Rises Modestly as Shares Consolidate Near Key ResistanceATR Trailing Stop - newsline.com
Maze Therapeutics to Present at William Blair and Goldman Sachs Healthcare Conferences in June 2024 - geneonline.com
Watch Maze Therapeutics CEO at Jefferies and Goldman health conferences in June - Stock Titan
J.P. Morgan Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Cuts Target Price to $53 - Moomoo
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares - AOL.com
Maze Therapeutics, Inc. Files Form 8-K with SEC: Company Details, Nasdaq Listing, and Contact Information - Minichart
Maze Therapeutics Analyst Ratings and Price Targets | NASDAQ:MAZE - Benzinga
Maze Therapeutics CFO Expands Role Amid Finance Leadership Change - TipRanks
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and Protara Therapeutics (TARA) - The Globe and Mail
H.C. Wainwright Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $110 - Moomoo
100% Of This Maze Therapeutics Insider's Holdings Were Sold - 富途牛牛
Maze Therapeutics CEO Jason Coloma sells $50,388 in stock By Investing.com - Investing.com Australia
Maze Therapeutics Insider Sold Shares Worth $393,354, According to a Recent SEC Filing - Moomoo
Maze Therapeutics CEO Jason Coloma sells $50,388 in stock - Investing.com
CEO Coloma trusts trim 1,938 Maze Therapeutics (MAZE) shares under 10b5-1 plan - Stock Titan
Maze Therapeutics (MAZE) CMO sells 15,000 shares, exercises options - Stock Titan
Maze Therapeutics, Inc. (MAZE) reports Q1 loss, beats revenue estimates - MSN
HighVista Strategies Sells Maze Therapeutics Shares in Q1 2026News and Statistics - IndexBox
HighVista Strategies Sells Shares of Maze Therapeutics Amid Stock Surge - Intellectia AI
JP Morgan Maintains Maze Therapeutics (MAZE) Overweight Recommendation - MSN
1.27%
1.43%
자본화:
|
볼륨(24시간):